诺瓦瓦克斯医药 NVAX 深 沪
已收盘 09-25 16:00:00 美东时间
10.63
+0.030
+0.28%
华盛通- 最 高10.79
- 今 开10.62
- 成交量 391.01万股
- 最 低 10.335
- 昨 收 10.60
- 总市值 17.53亿
- 52周最高 11.97
- 市盈率 静 4.18
- 换手率 2.37%
- 52周最低 6.20
- 委 比 -92.54%
- 总股本 1.65亿
- 历史最高 331.68
- 量 比 0.56
- 振 幅 4.29%
- 历史最低 3.5324
- 每 手 1
- 风险率 1.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多港股早知道 | 蔚来Q2实现收入总额为321.37亿元；比亚迪8月乘用车销量43.3万辆，同比增长16.7%
蔚来Q2实现收入总额为321.37亿元，同比增长69.1%；比亚迪8月乘用车销量43.3万辆，同比增长16.7%；先声药业与罗氏达成授权合作首付款7500万美元>>
09-02 07:54
9月2日美股收盘：道指跌逾400点，油价突破90美元，美联储加息概率升至68%
周二美股三大指数集体收跌，美国对伊朗发动新一轮空袭，推动油价走高；同时债券市场遭遇抛售，叠加市场对美联储下一步利率行动的猜测，令买家普遍持观望态度。 道...
09-02 04:30
Novavax Stock Climbs Monday: What's Going On?
Shares of Novavax Inc. (NASDAQ:NVAX) are trading higher Monday morning. The stock is extending its 30% monthly gains as investors respond positively to regulatory approvals across major jurisdictions for its updated protein-based COVID-19 vaccine ahead of the 2026–2027 autumn vaccination campaign, a...
08-31 23:38
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of Ascendis Pharma A/S (NASDAQ:ASND) rose sharply on Monday. On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma to resolve all global patent disputes rega...
08-31 22:30
Takeda gains approval of rusfertide for polycythemia vera
The US FDA approved Takeda Pharmaceutical's (TAK) Mimrylo (rusfertide), a first-in-class treatment for the rare blood disorder polycythemia vera. Mimrylo works by mimicking hepcidin, a hormone that na...
08-29 05:44
Novavax announces regulatory approvals for updated COVID shot
Novavax (NVAX) on Friday announced that the U.S., European Union, and Japan have approved the updated versions of its COVID-19 vaccine Nuvaxovid, developed with partners Sanofi (ANY) and Takeda (TAK),...
08-28 21:25
Novavax's Partners Receive Approvals For Nuvaxovid Formulation To Target SARS-CoV-2 XFG Variant
Novavax, Inc.'s (NASDAQ:NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European Union (EU) and Japan. These approvals position Novavax to continue earning royalties o...
08-28 20:34
Novavax Stock Rallies Tuesday: What's Happening?
Shares of Novavax Inc (NASDAQ:NVAX) are trading higher Tuesday morning as buying interest continues across late-stage vaccine developers. Here’s what investors need to know. Novavax shares are climbing with conviction. Why are NVAX shares rallying? Vaccine Pipeline Momentum And Sanofi Milestones Fue...
08-25 23:31
Notable healthcare headlines for the week: Moderna, Merck, and Twist Bioscience in focus
Wall Street’s major averages closed firmly higher on Friday, with Treasury yields largely steady and Bitcoin experiencing sharp intraday swings. The Dow Jones Industrial Average advanced 0.9%, the S&P...
08-23 21:05
Novavax Stock Moves Higher Wednesday: What's Driving the Action?
Shares of Novavax Inc (NASDAQ:NVAX) are trading higher Wednesday. The move comes as a major clinical victory in the oncology space generated widespread momentum across vaccine developers and the broader biotechnology sector. Novavax shares are climbing with conviction. Why are NVAX shares rallying? ...
08-20 00:33
